Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Psyence taps AstraZeneca veteran Neil Maresky as new CEO to impact mental health with psychedelics

Psyence taps AstraZeneca veteran Neil Maresky as new CEO to impact mental health with psychedelics

Psyence Group Inc. (CSE: PSYG) new CEO Dr. Neil Maresky joins Proactive to talk about his new appointment and his qualifications, including spending more than a decade at AstraZeneca Canada as Vice President of Scientific Affairs.

Maresky, a South African trained doctor, says he joined the psychedelics-focused life sciences group because of its ability to potentially impact mental health including depression, anxiety, PTSD, and end-of-life care.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK